Abstract:Ribosomally-synthesized and post-translationally-modified peptides (RiPPs) are a major class of natural products. It originates from a corresponding biosynthetic gene cluster where the genes for a precursor peptide and several post-translational modification (PTM) enzymes are located. The precursor peptide is translated by a ribosome, recognized on the N-terminal leader peptide and modified on the C-terminal core peptide by PTM enzymes, to finally give a structurally unique mature compound. So far, the RiPPs found by researchers only account for a small part of the family, and there are a large number of compounds remaining to be discovered. The S-adenosylmethionine radical (rSAM) enzyme family is one of the largest enzyme superfamilies, containing more than 22000 members. These enzymes are widely distributed in eukarya, bacteria and archaea and are considered to be one the earliest biocatalysts on earth which perform essential and inseparable functions in cells. As more substantial microbial genomic information becomes available, a large number of RiPPs are excavated as natural products by high-throughput analyses. Genome mining in microorganisms reveals great abundance of biosynthetic gene clusters consisting of co-occurring rSAM enzyme and RiPPs' peptide genes, mostly leading to complex bioactive compounds whether reported or not. Recently, three genera, Xenorhabdus, Yersinia, and Erwinia, are unified with the definition of XYE system, for they all employ a highly conserved rSAM enzyme responsible for modifying its adjacent peptide to create a distinctive C-C or C-O bond in the final RiPPs product. Yet complex compounds synthesized through the rSAM enzyme modifying a precursor peptide in the XYE system have rarely been reported. Through algorithm analysis, we monitored a biosynthetic gene cluster in the Xenorhabdus sp. KJ12.1 comforming a similar construction of that in an XYE system. We fully synthesized the precursor peptide and the rSAM enzyme genes from Xenorhabdus sp. KJ12.1, heterologously expressed the modifying system in Escherichia coli and successfully obtained a novel ribopeptide Xenopeptide. Structure analysis showed that the rSAM enzyme XenB is involved in the formation of two C-C bonds on the side groups of the precursor, one between tryptophan14(W14) and asparagine16 (N16), the other between tryptophan21(W21) and lysine23(K23). Although bioactivity tests proved the compound without a confirmed antimicrobial activity, we can still expect the utilization of the product elsewhere with its chemical complexity. These results indicate a developmental potential of combining computer technology and biological engineering. Our work provides a fundamentally theoretical basis for in-depth genome mining and a practically technical flow for finding modified compounds in microorganisms. The combination of genetic manipulation, biosynthetic characterization and structure determination is expected to further decipher the mechanistic enzymology involved in C-C crosslink formation. This strategy will shed light on the structure-activity relationships involved in the maturation of this subclade of RiPPs. Moreover, thorough biosynthetic engineering of Xenopeptide's precursor peptide and relevant enzymes through rational design and directed mutation will facilitate the development of a variety of Xenopeptide analogs with enhanced bioactivities. This paper will not only disclose the enzymatic underpinnings underlying the biosynthesis of C-C crosslinks, but also point out new directions for structural derivatization of bioactive peptides.

Exploring Bioactive Fungal RiPPs: Advances, Challenges, and Future Prospects

Discovery and Engineering of Ribosomally Synthesized and Post-Translationally Modified Peptide (ripp) Natural Products

Advancements in the Application of Ribosomally Synthesized and Post-Translationally Modified Peptides (RiPPs)

Opportunities and challenges of RiPP-based therapeutics

Challenges and advances in genome mining of ribosomally synthesized and post-translationally modified peptides (RiPPs)

Antifungal Peptides Produced by Actinomycetes and Their Biological Activities Against Plant Diseases.

Novel types of RiPP-modifying enzymes

Biosynthetic Investigation Of Phomopsins Reveals A Widespread Pathway For Ribosomal Natural Products In Ascomycetes

Current Advancements in Sactipeptide Natural Products

Structural Investigation Of Ribosomally Synthesized Natural Products By Hypothetical Structure Enumeration And Evaluation Using Tandem Ms

Cell-free biosynthesis and engineering of ribosomally synthesized lanthipeptides

Global Genome Mining Reveals the Distribution of Diverse Thioamidated RiPP Biosynthesis Gene Clusters

Mining the biosynthetic landscape of lactic acid bacteria unearths a new family of RiPPs assembled by a novel type of ThiF-like adenylyltransferases

P450‐Modified Multicyclic Cyclophane‐Containing Ribosomally Synthesized and Post‐Translationally Modified Peptides

New developments in RiPP discovery, enzymology and engineering

Expansion of RiPP biosynthetic space through integration of pan-genomics and machine learning uncovers a novel class of lanthipeptides

Engineering ribosomally synthesized and posttranslationally modified peptides as new antibiotics

Synthetic Biology Strategy to Discover a Novel Ribosomal Peptide, Xenopeptide

Comprehensive Biosynthetic Analysis of Human Microbiome Reveals Diverse Protective Ribosomal Peptides

Bioinformatic prediction and experimental validation of RiPP recognition elements

Engineering the biosynthesis of fungal nonribosomal peptides